<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452126</url>
  </required_header>
  <id_info>
    <org_study_id>UNM HRRC 11-030</org_study_id>
    <nct_id>NCT01452126</nct_id>
  </id_info>
  <brief_title>Minimum Effective Concentration of Ropivacaine for Brachial Plexus Block Via the Supraclavicular and Infraclavicular Approach, Femoral Nerve Block, Sciatic Nerve Block Via the Popliteal and Parasacral Approach</brief_title>
  <acronym>MEAC</acronym>
  <official_title>Minimum Effective Anesthetic Concentration of Supraclavicular Block, Infraclavicular Block, Femoral Nerve Block and Sciatic Nerve Block Via the Popliteal and Parasacral Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose finding study to identify the minimum effective anesthetic concentration
      (MEAC) of ropivacaine to produce insensate body parts sufficient for surgery in
      supraclavicular and infraclavicular approaches to the brachial plexus, parasacral and
      popliteal approaches to the sciatic nerve, femoral nerve and transversus abdominis plane
      (TAP) blocks in adults.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Departure of principal investigator
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective Concentration of Ropivacaine to Produce Surgical Anesthesia in 50% of Population</measure>
    <time_frame>1 day</time_frame>
    <description>The concentration of ropivacaine for each patient's nerve-block injection was determined per protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Complications</measure>
    <time_frame>3 days</time_frame>
    <description>All patients were followed up for complications such as bleeding, infection, side effects, nerve damage</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Surgical Anesthesia</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential allocation of ropivacaine concentration depending on the success or failure of surgical anesthesia of the previous patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine concentration</intervention_name>
    <description>Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block</description>
    <arm_group_label>Ropivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists physical status I to III (patients may be
             healthy or have systemic disease, but any disease does not pose a constant threat to
             life, and patients are neither moribund, nor not expected to survive without the
             operation).

          -  Age 18 or above

          -  Undergoing elective ambulatory surgery of the upper limb (excluding the shoulder),
             lower limb (excluding the hip), or lower abdomen with sensory blockade as part of the
             pain management plan.

        Exclusion Criteria:

          -  Body mass index of &gt;35 kg/m2 (higher chance of failure)

          -  Deformities of the leg (for patients in the parasacral, femoral, and popliteal
             groups), or the chest or shoulder (for patients in the supraclavicular,
             infraclavicular, and TAP groups)

          -  Preexisting infection at the injection site

          -  Existing neurologic disease

          -  Allergy to local anesthetic agents

          -  Severe respiratory disease

          -  Coagulopathy

          -  Any other contraindication to the block being considered

          -  Patients requiring total motor blockade as well as sensory blockade
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Lam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy of Mexico Outpatient Surgical and imaging service</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>October 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2016</results_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Timothy R Petersen</investigator_full_name>
    <investigator_title>Research Information Specialist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ropivacaine</title>
          <description>Sequential allocation of ropivacaine concentration depending on the success or failure of surgical anesthesia of the previous patient
Ropivacaine concentration: Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ropivacaine</title>
          <description>Each patient received ropivacaine-based nerve blockade at a fixed volume, with concentration determined per protocol</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effective Concentration of Ropivacaine to Produce Surgical Anesthesia in 50% of Population</title>
        <description>The concentration of ropivacaine for each patient's nerve-block injection was determined per protocol.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Femoral Nerve Block</title>
            <description>Ropivacaine-based blockade of the femoral nerve, with concentration per protocol.</description>
          </group>
          <group group_id="O2">
            <title>Supraclavicular Blockade</title>
            <description>Ropivacaine-based blockade of the brachial plexus nerves via a supraclavicular approach, with concentration per protocol.</description>
          </group>
          <group group_id="O3">
            <title>Infraclavicular Blockade</title>
            <description>Ropivacaine-based blockade of the brachial plexus nerves via an infraclavicular approach, with concentration per protocol.</description>
          </group>
          <group group_id="O4">
            <title>Popliteal Nerve Block</title>
            <description>Ropivacaine-based blockade of the popliteal nerve, with concentration per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Concentration of Ropivacaine to Produce Surgical Anesthesia in 50% of Population</title>
          <description>The concentration of ropivacaine for each patient's nerve-block injection was determined per protocol.</description>
          <units>percentage concentration, ropivacaine</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09"/>
                    <measurement group_id="O2" value="0.11"/>
                    <measurement group_id="O3" value="0.16"/>
                    <measurement group_id="O4" value="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Complications</title>
        <description>All patients were followed up for complications such as bleeding, infection, side effects, nerve damage</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine</title>
            <description>Sequential allocation of ropivacaine concentration depending on the success or failure of surgical anesthesia of the previous patient
Ropivacaine concentration: Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Complications</title>
          <description>All patients were followed up for complications such as bleeding, infection, side effects, nerve damage</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ropivacaine</title>
          <description>Sequential allocation of ropivacaine concentration depending on the success or failure of surgical anesthesia of the previous patient
Ropivacaine concentration: Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Failure of regional anesthesia</sub_title>
                <description>As this was a dose-finding study, it was expected that some patients would experience failure of regional anesthesia.</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed. Confidence intervals for primary outcome are not reliable and therefore not reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Tim Petersen</name_or_title>
      <organization>UNM Department of Anesthesiology</organization>
      <phone>5052722610 ext 505</phone>
      <email>timpetersen@salud.unm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

